PDS Biotechnology Corporation

136 articles with PDS Biotechnology Corporation

• PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial ResultsCompany to host conference call and webcast today, May 11, 2022, at 8:00 AM EDT

  5/11/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune ® and Infectimune™ T-cell activating technologies, will discuss its financial results for the quarter ended March 31, 2022, and provide a business update on its conference call today.

• PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results

  4/28/2022

  PDS Biotechnology Corporation today announced that the Company will release financial results for the first quarter of 2022 on Wednesday, May 11, 2022, before the market opens.

• PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

  4/27/2022

  PDS Biotechnology Corporation announced the titles of two abstracts accepted for poster presentations during the 2022 American Society of Clinical Oncology Annual Meeting being held from June 3-7, 2022.

• PDS Biotech Chief Medical Officer, Lauren V. Wood, to Chair Session at the World Vaccine Congress

  4/20/2022

  PDS Biotechnology Corporation today announced Lauren V. Wood, M.D. will be chairing Day 2 of the Cancer and Immunotherapy Vaccines Conference at the World Vaccine Congress being held in Washington, DC.

• PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

  4/19/2022

  PDS Biotechnology Corporation announced that on April 18, 2022, the Company received $1.2 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss program for State Fiscal Year 2021.

• PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 08, 2022

  4/8/2022

  PDS Biotechnology Corporation announced that on April 6, 2022 PDS Biotech granted nonstatutory stock options to Robert Imani, M.D., PhD, PDS Biotech’s Vice President Medical Director to purchase 70,000 shares of PDS Biotech common stock.

• PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results

  3/31/2022

  PDS Biotechnology Corporation provided a business update and announced its financial results for the year ended December 31, 2021.

• PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call

  3/22/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that it has changed the date of its previously announced 2021 fourth quarter and full year earnings release call from Wednesday, March 23, 2022 to 8:00 AM EDT on Thursday, March 31, 2022.

• PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers

  3/15/2022

  PDS Biotechnology Corporation today announced that the National Cancer Institute (NCI) has achieved the intended enrollment objective of 30 patients in the checkpoint inhibitor (CPI).

• PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results

  3/9/2022

  PDS Biotechnology Corporation announced the Company will release financial results for the three- and twelve-month periods ended December 31, 2021, on Wednesday, March 23, 2022, before the market opens.

• PDS Biotechnology to Present at the 32nd Oppenheimer Annual Healthcare Conference

  3/1/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that its management will present at the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 15, 2022.

• PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

  2/24/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology, today announced the presentation of preliminary safety data.

• PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

  2/15/2022

  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced the initiation of an Investigator-Initiated Trial (ITT), MC200710, for PDS0101 alone or in combination with the checkpoint inhibitor, KEYTRUDA®.

• PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

  2/2/2022

  PDS Biotechnology Corporation today announced its VERSATILE-002 Phase 2 study for the treatment of advanced human papillomavirus (HPV)-associated head and neck cancer achieved its preliminary objective response benchmarks.

• PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine

  1/27/2022

  PDS Biotechnology Corporation today announced preclinical data for its universal flu vaccine, which was shown to be effective against multiple strains of the influenza virus.

• PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference

  1/18/2022

  PDS Biotechnology Corporation announced that its management will present at the B. Riley Securities Virtual Oncology Conference on January 28, 2022.

• PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium

  1/12/2022

  PDS Biotechnology Corporation announced that the initial safety data from its VERSATILE-002 study has been accepted for presentation at the 2022 Multidisciplinary Head and Neck Cancers Symposium being held February 24-26, 2022, at the JW Marriott Phoenix Desert Ridge Resort and Spa, Phoenix, AZ.

• PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy Extends patent protection of PDS0101 by the United States Patent and Trademark Office Until October 2037

  1/10/2022

  PDS Biotechnology Corporation announced that it has been granted U.S. Patent Application No. 15,724,818 titled “Novel HPV16 Non HLA-Restricted T-cell Vaccines, Composition and Methods of Use Thereof” by the United States Patent and Trademark Office.

• PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference

  1/5/2022

  PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced that its management will present at the H.C. Wainwright Bioconnect Virtual Conference.

• PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Dec 23, 2021

  12/23/2021

  PDS Biotechnology Corporation announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS Biotech.